Quick Answer
Serina Therapeutics, Inc. reported Total Assets of $6.95 million for the year ending 2025.
- Serina Therapeutics, Inc. showed an increase of +3.4% in Total Assets from 2024 to 2025.
- This data is from Serina Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2018: $10.67 million | Q1 2019: $12.32 million | Q2 2019: $10.26 million | Q3 2019: $8.18 million | Q1 2020: $5.09 million | Q2 2020: $4.76 million | Q3 2020: $4.20 million | Q1 2021: $3.16 million | Q2 2021: $2.54 million | Q3 2021: $2.43 million | Q1 2022: $2.72 million | Q2 2022: $2.58 million | Q3 2022: $2.01 million | Q1 2023: $12.53 million | Q2 2023: $12.28 million | Q3 2023: $12.21 million | Q1 2024: $10.86 million | Q2 2024: $10.71 million | Q3 2024: $7.44 million | Q1 2025: $6.73 million | Q2 2025: $8.94 million | Q3 2025: $12.41 million.
- Over the full 9 years of available data (2017 to 2025), Serina Therapeutics, Inc.'s Total Assets has declined by 27.8%.
- Historical annual values: Fiscal year 2025: $6.95 million | Fiscal year 2024: $6.72 million | Fiscal year 2023: $8.97 million | Fiscal year 2022: $3.24 million | Fiscal year 2021: $3.15 million | Fiscal year 2020: $3.93 million | Fiscal year 2019: $7.44 million | Fiscal year 2018: $10.67 million | Fiscal year 2017: $9.63 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: